Sanofi-Aventis (SNY) Receives a Downgrade
Exane BNP Paribas has cut the rating for shares of Sanofi-Aventis (SNY) to a solid “Underperform” in a very recent research note issued to investors and clients on 10 December. SNY’s previous rating by the firm was a “Neutral”.
From a total of 3 analysts covering Sanofi-Aventis (SNY) stock, 1 rate it a ”Buy”, 0 a “Sell”, and 2 a ”Hold”. This means that 33% of the ratings are positive. Sanofi-Aventis was the topic of 2 analyst reports since October 15, 2015 according to the firm StockzIntelligence Inc. Bernstein downgraded shares on November 9 to “Mkt Perform” rating.
Approximately 371,815 shares of stock traded hands. Sanofi SA (ADR) (SNY) has declined 13.78% since May 7, 2015 and is downtrending. It has underperformed by 11.84% the S&P500.
Sanofi SA is a healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. The company has a market cap of $109.93 billion. The Firm is organized around three principal activities: Pharmaceuticals, Human Vaccines via Sanofi Pasteur, and Animal Health via Merial. It has 20.68 P/E ratio. The Firm invests in emerging markets, diabetes solutions, vaccines, consumer health care, animal health, genzyme and other products.
According to Zacks Investment Research, “Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.” Get a free copy of the Zacks research report on Sanofi SA (ADR) (SNY).